The FDA recently approved Neutroval, Similar to Amgen’s Neupogen, for Severe Chronic Neutropenia

The FDA recently approved Sicor Biotech’s tbo-filgrastim (Neutroval).  It is a short-acting recombinant granulocyte colony-stimulating factor (G-CSF) agent. It is marketed as Tevagrastim in Europe, where tbo-filgrastim is classified as biosimilar to Amgen’s G-CSF product, Neupogen, for Severe Chronic Neutropenia.   Tbo-filgrastim is intended for use in adults who have nonmyeloid malignancies and are taking chemotherapy drugs that cause a substantial decrease in the production of neutrophils in the bone marrow. This reduction in neutrophils may lead to febrile neutropenia.  Tbo-filgrastim stimulates the bone marrow to increase the production of neutrophils. It is administered as an injection beginning 24 hours after chemotherapy treatment.

Read more at ASCO Post

Ariana-Leilani needs medicine for her severe chronic neutropenia, please sign her petition:


Related articles

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s